Alvin Furuike
Pulmonary Disease · Honolulu, HINPI 1689684045
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 341 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,669 and has fallen 90.2% since, to $260 in 2025.
Across 341 payments — averaging $29.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Insmed, Inc.$2K
- Sanofi$2K
- Boehringer Ingelheim$666
- Jazz Pharmaceuticals Inc.$627
- plus $2K from 17 others
What the payments were for
- Food & beverage$10,00999%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 124 | $2,004 |
| AstraZeneca | 70 | $1,832 |
| Insmed, Inc. | 65 | $1,757 |
| Sanofi | 17 | $1,603 |
| Boehringer Ingelheim | 17 | $666 |
| Jazz Pharmaceuticals Inc. | 11 | $627 |
| Genentech USA, Inc. | 6 | $430 |
| Regeneron Healthcare Solutions, Inc. | 9 | $351 |
| Mallinckrodt Hospital Products Inc. | 1 | $150 |
| Eisai Inc. | 1 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Advanced Respiratory, Inc | 2 | $66 |
| Teva Pharmaceuticals USA, Inc. | 3 | $65 |
| Mylan Specialty L.p. | 1 | $56 |
| Actelion Pharmaceuticals US, Inc. | 2 | $44 |
| AbbVie(2 entities) | 2 | $44 |
| Philips North America LLC | 2 | $43 |
| United Therapeutics Corporation | 2 | $33 |
| Harmony Biosciences LLC | 1 | $27 |
| Baxter Healthcare | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Grifols USA, LLC | 1 | $20 |
| Shire North American Group Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,089 in reported general payments places this provider in the 75th percentile of 44 pulmonary disease providers in Hawaii.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $21,057 |
| Montelukast Sodium | 13 | $699 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $2,004 | $21,05715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 44 pulmonary disease providers in Hawaii.
Other pulmonary disease in Honolulu
- Takkin LoHonolulu$324K
- Bradley TokeshiHonolulu$41K
- Ernie YimHonolulu$20K
- Eric CrawleyHonolulu$17K
- Samuel EvansHonolulu$15K
- Ronson SatoHonolulu$14K
- James YangHonolulu$8K
- Katsufumi NishidaHonolulu$8K
- Sheri Shimizu-SaitoHonolulu$8K
- Jennifer KayaHonolulu$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.